SONN — Sonnet Biotherapeutics Holdings Share News
0.000.00%
Last trade - 00:00- $26.33m
- $26.01m
- $0.02m
Brief: Sonnet BioTherapeutics Announces 1-For-14 Reverse Stock Split
Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended in June - Earnings Summary
Sonnet Biotherapeutics Holdings Inc expected to post a loss of 14 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Novavax, Signet Jewelers, Zendesk, Roblox
U.S. STOCKS ON THE MOVE-Tesla, Roblox, Novavax, Couchbase
U.S. STOCKS ON THE MOVE-Deere, Signet Jewelers, Tesla, Bluejay Diagnostics
Penny stock Sonnet Bio surges on positive pre-clinical data
Brief: Sonnet Biotherapeutics Announces Results From Preclinical Combination Study Of SON-1010 With Anti-PD1 Checkpoint Inhibition
Brief: Sonnet Biotherapeutics Holdings Inc - QTRLY Loss Per Share $0.14
U.S. STOCKS ON THE MOVE-Kohl's Corp, Biogen, card companies
U.S. STOCKS ON THE MOVE-Sonnet Bio, Spotify, Lockheed Martin, Apellis Pharma
Sonnet soars after FDA approves human trial of cancer treatment
U.S. STOCKS ON THE MOVE-Starbucks, Carnival Corp, chip stocks
Brief: Sonnet Biotherapeutics Says FDA Has Cleared Co's Investigational New Drug Application For SON-1010
Brief: Sonnet Biotherapeutics Holdings Inc - As Of Dec 31, 2021, Sonnet Had $19.4 Million Cash On Hand
Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended in September - Earnings Summary
Sonnet Biotherapeutics Holdings Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Sonnet Receives Letter From Listing Qualifications Staff Of Nasdaq Stock Market
Brief: Sonnet Biotherapeutics Initiates Manufacturing Process For SON-1410